Thank you for correcting the text in this article. Your corrections improve Papers Past searches for everyone. See the latest corrections.

This article contains searchable text which was automatically generated and may contain errors. Join the community and correct any errors you spot to help us improve Papers Past.

Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image
Article image

A.I.D.S. patient succumbs

NZPA-AFP Paris A patient being treated at a Paris hospital with a drug heralded as a? breakthrough in the fight against A.I.D.S. has died. Professor Philippe Even, one of the three doctors from Laennec Hospital, where tests were being done with the drug cyclosporineA — normally used to prevent the rejection of transplant organs — did not say when the patient had died.

The patient “had initially suffered from two serious cerebral and pulmonary infections” and despite an encouraging biological

response he had died of a “medullary aplasia” and liver complications linked with a viral infection and rejection of treatment. He said that the patient’s rejection of treatment was unconnected with the cyclosporine.

Professor Even and two colleagues at Laennec Hospital, Jean-Marie Andrieu and Alain Venet — announced last month that tests on six patients had produced “biologically extraordinary” results. But the international medical establishment reacted with scepticism to their assertions, which were said to be premature.

Permanent link to this item

https://paperspast.natlib.govt.nz/newspapers/CHP19851113.2.63.6

Bibliographic details

Press, 13 November 1985, Page 8

Word Count
157

A.I.D.S. patient succumbs Press, 13 November 1985, Page 8

A.I.D.S. patient succumbs Press, 13 November 1985, Page 8

Help

Log in or create a Papers Past website account

Use your Papers Past website account to correct newspaper text.

By creating and using this account you agree to our terms of use.

Log in with RealMe®

If you’ve used a RealMe login somewhere else, you can use it here too. If you don’t already have a username and password, just click Log in and you can choose to create one.


Log in again to continue your work

Your session has expired.

Log in again with RealMe®


Alert